Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ELYM Eliem Therapeutics > Detailed Quotes

ELYM Eliem Therapeutics

3.080
-0.100-3.14%
Close 10/06 16:00 ET
3.0800.0000.00%
Post Mkt Price 10/06 16:00 ET
High
3.080
Open
3.050
Turnover
4.40K
Low
3.050
Pre Close
3.180
Volume
1.38K
Market Cap
81.83M
P/E(TTM)
Loss
52wk High
19.620
Shares
26.57M
P/E(Static)
Loss
52wk Low
2.520
Float Cap
13.36M
Bid/Ask %
33.33%
Historical High
29.690
Shs Float
4.34M
Volume Ratio
0.01
Historical Low
2.520
Dividend TTM
--
Div Yield TTM
--
P/B
0.58
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.03%
Amplitude
0.94%
Avg Price
3.195
Lot Size
1
Float Cap
13.36M
Bid/Ask %
33.33%
Historical High
29.690
Shs Float
4.34M
Volume Ratio
0.01
Historical Low
2.520
Dividend TTM
--
P/B
0.58
Dividend LFY
--
Turnover Ratio
0.03%
Amplitude
0.94%
Avg Price
3.195
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.
CEO: Mr. Robert W. Azelby
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...